Pro-Pharmaceuticals partners with UMass Lowell

Pro-Pharmaceuticals Inc. of Newton announced today that it has entered a research collaboration with University of Massachusetts Lowell.

The collaboration is to evaluate Pro-Pharmaceuticals' lead product candidate, Davanat, with chemotherapy drugs, said the company, which noted that UML has leading edge capabilities in nanotechnology and polymer characterization.

In a statement, David Platt, Pro-Pharmaceuticals chairman and chief executive, said, "We continue to advance the development of Davanat, our lead product candidate in clinical trials, and the work from this collaboration will help further expand its potential as a first-in-class, targeted drug delivery system."
(By Chris Reidy, Globe staff)